Zhejiang University to Transfer Five Patents on Modified Lactoferrin (Apo-LfMA) for Therapeutic Applications at RMB 840,000

Recently, Zhejiang University released a public notice on the conversion of scientific and technological achievements, proposing to transferFive Patents on the Preparation of Modified Lactoferrin and Its Applications in the Medical FieldBundle transfer, with a conversion price of840,000 yuan. The inventors of this series of achievements areZhu Yang, Zhang Liwen, Ren Tanchen, and their team from Zhejiang University.

Although natural lactoferrin possesses iron-binding capabilities, its binding capacity is often “stretched to the limit” when addressing acute pathological conditions. To tackle this challenge, the team has developedA Novel Methacrylated Lactoferrin (Apo-LfMA). Experimental data show that the technology has successfullySurpassing the Performance Limits of Natural Proteins:Significantly increase the number of heme-binding sites on lactoferrin from the natural 1–2 to7–13 units, increasing the iron saturation content from the traditional approximately 1.4 mg/g to>10 mg/g. This "enhanced" lactoferrin not only clears free heme and iron ions more efficiently, but can also be flexibly formulated into injections or hydrogels, providing a novel therapeutic solution for myocardial and renal ischemia-reperfusion injury as well as iron overload disorders.

Excessive accumulation of free heme and iron ions,It has long been a core driver of the exacerbation of various critical illnesses. In pathological scenarios such as myocardial ischemia-reperfusion, renal ischemia-reperfusion, cerebral infarction, and hemolytic diseases, cell rupture leads to the instantaneous release of large amounts of heme and iron ions. Studies have shown that free hemeOnly 1 μM requiredconcentrations are sufficient to induce cell death, reflecting their extremely high toxicity. These “toxic factors” not only trigger intense oxidative stress but also induce ferroptosis, leading to severe secondary organ injury and substantially increasing the difficulty of clinical treatment as well as the risk of patient mortality.

However, existing therapeutic approaches exhibit a significant "dose-response" limitation in clearing these free toxins.From the perspective of heme clearance,Currently Recognized as the StrongestHemopexin-Binding Protein, possessing only 1–2 heme-binding sites in its molecular structure. This limited binding capacity means that clearing the explosive surge of heme in the body often requires administering massive doses of protein preparations, which not only significantly drives up treatment costs but also restricts clearance efficiency, making it difficult to rapidly curb the spread of damage within the “golden window” for emergency intervention.

From the perspective of iron ion chelation,Although natural lactoferrin is regarded as a high-quality iron chelator, it is also limited by its own molecular structure. Natural lactoferrin consists of two globular lobes and can theoretically chelate only two iron ions, with an iron saturation capacity of approximately 1.4 mg/g (i.e., an iron content of about 0.14%). When confronted with high concentrations of free iron in pathological microenvironments, the adsorption capacity of natural lactoferrin rapidly becomes saturated, preventing rapid and thorough reduction of environmental iron levels.

Furthermore,In the field of antimicrobial therapy,Iron is an essential nutrient for bacterial growth and reproduction. The relatively weak iron-chelating capacity of natural lactoferrin makes it difficult to effectively inhibit bacterial growth through “nutritional deprivation,” rendering it inadequate in addressing the increasingly severe challenge of drug-resistant bacterial infections. Therefore, there is an urgent clinical need for a novel lactoferrin technology that can overcome the structural limitations of the natural protein and possess an “ultra-high adsorption capacity,” so as to fundamentally resolve the key issues of limited binding sites and low binding capacity associated with current therapies for iron overload and heme-induced injury.

To address the binding bottleneck of natural lactoferrin, this patented technology utilizesMethacrylation Modificationas the core breakthrough, successfully constructed modified lactoferrin with super-strong adsorption capacity—Apo-LfMA. This innovative modification strategy has achieved a disruptive leap over traditional technologies across multiple dimensions, including microstructure, binding efficacy, and application formats.

In terms of adsorption efficiency,By precisely controlling the degree of grafting with methacrylic anhydride, this technology induces a greater exposure of hydrophobic domains in lactoferrin and alters the charge distribution on the protein surface. This structural “remodeling” significantly enhances its capacity to “capture” toxic factors:(1) Doubling of Heme-Binding Capacity:The heme-binding sites on lactoferrin have been substantially expanded from the natural 1–2 to 7–13, meaning that the efficiency of free heme clearance by a single protein molecule is increased several-fold.(2) Qualitative change in iron adsorption capacity:Surpassing the theoretical limitation that natural lactoferrin possesses only two iron-binding sites, we increased the number of iron-binding sites to 20; the iron saturation content rose from approximately 1.4 mg/g in its natural state to over 10 mg/g (with experimental values reaching up to 14.43 mg/g), achieving a nearly tenfold increase in adsorption capacity.

In terms of mechanism of action,The team elucidated the underlying scientific mechanism: methacryloyl groups grafted onto lysine residues convert the originally positively charged groups into neutral ones, significantly reducing the positive charge density on the protein surface. This modification effectively diminishes the electrostatic repulsion between the protein and the positively charged iron at the heme center, facilitating deeper penetration of heme into the protein’s interior for binding, thereby substantially enhancing both affinity and binding capacity.

Furthermore,In terms of the plasticity of dosage forms,This technology also demonstrates excellent performance. Apo-LfMA can not only be formulated as a solution for intravenous injection, but also introducesPhoto-crosslinking PropertiesBy leveraging the double-bond structures on its surface, it can be further engineered into photo-crosslinkable hydrogels or functionalized microspheres. This multimodal adaptability enables systemic toxin clearance via intravenous administration, as well as localized formation of a “magnetic sponge” at lesion sites—such as in the myocardium and kidneys—through in situ injection, thereby achieving precise and sustained treatment of ischemia-reperfusion injury. This establishes a complete technological loop spanning from microscopic molecular modification to macroscopic formulation applications.

Currently, with the intensifying aging of the population, the demand for treatment of cardiovascular and cerebrovascular diseases as well as critical illnesses is experiencing explosive growth. However, there remains a lack of specific therapeutic interventions in the market to address the challenge of ischemia-reperfusion injury. Although traditional chemical iron chelators have been used for a longer period, they often face biocompatibility challenges such as short half-lives and significant toxic side effects; meanwhile, natural biological agents are limited by their “low-efficiency” binding capacity, making it difficult to meet the needs of acute and critical care.

The emergence of this modified lactoferrin technology has filled the market gap where “high efficacy and safety are difficult to achieve simultaneously,” demonstrating significant potential for commercial translation:

In the field of critical care and emergency medicine,This technology is poised to become a “cellular protective shield” for patients with myocardial infarction, cerebral infarction, and kidney injury. In the context of myocardial ischemia-reperfusion injury, Apo-LfMA can rapidly adsorb heme and iron ions that are explosively released at the lesion site, acting like a “sponge.” This effectively blocks the ferroptosis pathway, reduces the area of myocardial infarction, and preserves cardiac function.

In the fields of infection control and functional dressings,This technology, with its unique “"Iron-Sequestration" Antibacterial Mechanism, offering new insights for addressing the issue of antibiotic resistance. Photocrosslinked hydrogels or microspheres prepared using Apo-LfMA can be developed into high-end functional wound dressings or fillers. These materials promote wound healing while achieving broad-spectrum antimicrobial activity by depriving bacteria of iron, an element essential for their growth, thereby demonstrating significant clinical utility.

In terms of product development strategy,This technology features “"Integration of Pharmaceuticals and Medical Devices"a flexible translation pathway. It can be developed as an innovative biologic drug for the treatment of systemic hemolytic diseases or sepsis; alternatively, it can be formulated as a Class III medical device (such as hydrogels or microspheres) for precise intervention at local lesions.

In summary, this modified lactoferrin technology, which combines ultra-high adsorption capacity, excellent biocompatibility, and adaptability across multiple scenarios, is poised to secure a significant position in the future biomedical and high-end medical device markets, bringing revolutionary changes to the treatment of iron overload-related diseases.